Scholars Central

Conference abstractPublished 16 May 2016

Clinical metabonomics for biomarker discovery of malignant pleural effusions (MPE)

Authors: Ching-wan Lam

The University of Hong Kong, Hong Kong

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aim: Clinical metabonomics has been widely used in advanced laboratory medicine for the study of disease mechanism and biomarker discovery. Here, we will extend the use of clinical metabonomics to develop new screening test for malignant pleural effusions (MPE). Methods: 32 malignant and 18 non-malignant PE samples will be analyzed using reversed-phase liquid chromatography-tandem mass spectrometry (LC-MS/MS). Biomarkers for MPE will be determined by metabolome-wide association studies (MWAS) using Receiver Operating Characteristic Curve Explorer and Tester (ROCCET). All markers will be filtered using a metabolome-wide significance level (MWSL) at p-value ≤ 2×10−5. Results: 2731 and 3137 markers were detected in positive and negative ESI spectra respectively. Free fatty acids (FFAs) 16:0, 18:1 and 18:2 were significantly increased in MPE. FFA 18:1 (oleic acid) showed the largest area-under-ROC of 0.96 (95% CI: 0.87–1.00) with sensitivity of 84% and specificity of 100.0% (p-value: 8.23×10−8). Discussion: Pleural fluid oleic acid is a novel biomarker for screening MPE.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Ching-wan Lam”